Boston Partners’s Harvard Bioscience HBIO Stock Holding History

Boston Partners’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-20,733	Closed	-$591K	–	732
2024 Q2	$591K	Buy	+20,733	New	+$727K	﹤0.01%	647

Other funds holding HBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $2.02B AUM 40.6% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.46B AUM 78.13% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Boston Partners's HBIO Position: Q3 2024 in Review

Boston Partners sold out of Harvard Bioscience (HBIO) in Q3 2024, closing a stake of 20,733 shares — an estimated $591K sold.

Boston Partners first reported a position in HBIO in Q2 2024 and held it in 1 quarter. The position peaked at $591K in Q2 2024. 95 funds tracked by Wall St. Rank hold HBIO as of Q3 2024.

Boston Partners reported no remaining Harvard Bioscience position as of Q3 2024 after selling out during the quarter.
Boston Partners sold 20,733 Harvard Bioscience shares in Q3 2024, an estimated $591K.
Boston Partners first reported a position in Harvard Bioscience in Q2 2024 and held it in 1 quarter.
Boston Partners's Harvard Bioscience position peaked at $591K in Q2 2024.
95 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2024.

Based on Boston Partners's 13F filing for Q3 2024, filed 12 Nov 2024.